Kees van Grootheest
Research Subjects
Research Interests
Kees van Grootheest has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Eugène P. van Puijenbroek
Groningen Research Institute of Pharmacy, Pharmacotherapy, -Epidemiology and -Economics, University of Groningen, Groningen, The Netherlands
6 shared publications - Linda Härmark
Drug Safety Research Unit, Southampton, UK
2 shared publications Lolkje T.W. de Jong-Van Den Berg
Department of Social Pharmacy and Pharmacoepidemiology, GUIDE
2 shared publicationsLolkje de Jong-Van Den Berg
University of Groningen
2 shared publicationsM Heeringa
2 shared publicationsAnneke Passier
’s-Hertogenbosch
1 shared publication
Latest Publications
- 30 August 2012
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 22 (3) , 250-255
Representativeness of diabetes patients participating in a web‐based adverse drug reaction monitoring system
Purpose Lareb Intensive Monitoring, LIM, is a non‐interventional observational cohort method which follows first‐time users of certain drugs during a certain period of time and collects information about adverse drug reactions, ADRs. In order for LIM to be a useful pharmacovigilance tool, it is important to know whether the LIM population is comparable to the whole population using the drug. The aim of this study is to compare the LIM diabetes population with an external diabetes reference population on characteristics that may influence the patient's susceptibility for ADRs. Methods In this study, a LIM diabetes population was compared to a reference diabetes population derived from The Groningen Initiative to ANalyse Type 2 diabetes Treatment project. Comparisons were made regarding age, gender, body mass index and polypharmacy, as well as diabetes medication used and disease/treatment duration. Results LIM patients were more often men (58.5% vs 50.8%) and in general younger (59.1 vs 64.7 years) and healthier, by that meaning they had a higher percentage of de novo treated patients (55.5% vs 53.2%), a shorter diabetes treatment duration (3.7 vs 5.5 years) and used less co‐medication than patients in the reference population. Conclusions This study shows that diabetes patients participating in a web‐based intensive monitoring system differ from a reference population. The observed differences might lead to an underestimation of ADRs, but it is not clear whether this would also influence the type or time‐course of the reported ADRs. When interpreting results from LIM studies, one should take these differences into account. Copyright © 2012 John Wiley & Sons, Ltd.
- 30 August 2012
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 22 (3) , 250-255
Representativeness of diabetes patients participating in a web‐based adverse drug reaction monitoring system
Purpose Lareb Intensive Monitoring, LIM, is a non‐interventional observational cohort method which follows first‐time users of certain drugs during a certain period of time and collects information about adverse drug reactions, ADRs. In order for LIM to be a useful pharmacovigilance tool, it is important to know whether the LIM population is comparable to the whole population using the drug. The aim of this study is to compare the LIM diabetes population with an external diabetes reference population on characteristics that may influence the patient's susceptibility for ADRs. Methods In this study, a LIM diabetes population was compared to a reference diabetes population derived from The Groningen Initiative to ANalyse Type 2 diabetes Treatment project. Comparisons were made regarding age, gender, body mass index and polypharmacy, as well as diabetes medication used and disease/treatment duration. Results LIM patients were more often men (58.5% vs 50.8%) and in general younger (59.1 vs 64.7 years) and healthier, by that meaning they had a higher percentage of de novo treated patients (55.5% vs 53.2%), a shorter diabetes treatment duration (3.7 vs 5.5 years) and used less co‐medication than patients in the reference population. Conclusions This study shows that diabetes patients participating in a web‐based intensive monitoring system differ from a reference population. The observed differences might lead to an underestimation of ADRs, but it is not clear whether this would also influence the type or time‐course of the reported ADRs. When interpreting results from LIM studies, one should take these differences into account. Copyright © 2012 John Wiley & Sons, Ltd.
- 1 January 2012
- Published by SAGE Publications in International Journal of Risk & Safety in Medicine
- Vol. 24 (2) , 73-80
The rosiglitazone decision process at FDA and EMA. What should we learn?
In September 2010 the EMA decided to suspend the market authorisation of rosiglitazone, while the FDA decided to restrict the use of rosiglitazone. These actions were taken approximately 10 years after the introduction of rosiglitazone, because rosig
- 1 January 2012
- Published by SAGE Publications in International Journal of Risk & Safety in Medicine
- Vol. 24 (2) , 73-80
The rosiglitazone decision process at FDA and EMA. What should we learn?
In September 2010 the EMA decided to suspend the market authorisation of rosiglitazone, while the FDA decided to restrict the use of rosiglitazone. These actions were taken approximately 10 years after the introduction of rosiglitazone, because rosig
- 1 March 2011
- Published by Springer Nature in Drug Safety
- Vol. 34 (3) , 221-231
Intensive Monitoring of Pregabalin
Background: Pregabalin is one of the first drugs registered for the treatment of neuropathic pain. It is also indicated as adjuvant therapy in the treatment of epilepsy and for generalized anxiety disorder. Pregabalin is a GABA analogue and exerts its effect by binding to the α2-δ subunit of voltage-gated calcium channels, leading to a decreased synaptic release of neurotransmitters. Objective: To gain insight into the safety and user profile of pregabalin in daily practice, reported by patients via a web-based intensive monitoring system based at the Netherlands Pharmacovigilance Centre Lareb. Methods: Lareb Intensive Monitoring is an observational prospective cohort study with no limiting inclusion or exclusion criteria compared with clinical trials. First-time users of pregabalin were identified through the first prescription signal in intensive monitoring participating pharmacies between 1 August 2006 and 31 January 2008. Eligible patients received information about the pregabalin study in the pharmacy. When registering online, patient characteristics and information about pregabalin and other concomitant drug use were collected. After registration, the patient received questionnaires by e-mail 2 weeks, 6 weeks, 3 months and 6 months after the start of pregabalin. In these questionnaires, possible adverse drug reactions (ADRs) were addressed. Reactions not labelled in the Summary of Product Characteristics of pregabalin, and reactions that were labelled but were interesting for other reasons, were analysed on a case-by-case basis. Results: In total, 1373 patients filled in the online registration form. The average age of participants was 54.5 years (range 11–89), with 58.0% being female. The indication for pregabalin use was neuropathic pain in 85.9% of participants. The average daily dose was 201 mg, and 80.5% of all users used pregabalin capsule 75 mg. All patients who registered for the study were sent a questionnaire; 1051 (76.5%) patients filled in at least one questionnaire. There were no statistically significant differences found regarding sex, age or daily dosage between this latter group compared with the patients who registered for the study but did not fill in a questionnaire. At least one possible ADR was reported by 69.3% of patients and serious ADRs were reported by 11 patients. The five most frequently reported possible ADRs were dizziness, somnolence, feeling drunk, fatigue and increased weight. Four associations were further analysed. Headache was analysed because of its high frequency. The time to onset ranged from a few hours to 5 months, with a median time to onset of 2 days. In 15 reports the headache passed without withdrawing the drug, and in ten cases the headache disappeared after drug withdrawal. Upper abdominal pain, a possible drug interaction between pregabalin and blood glucose-lowering agents, and suicidal ideation were considered to be signals. Conclusions: Web-based intensive monitoring is an observational prospective cohort study. It will therefore provide a picture of the use of pregabalin and its ADRs in daily practice. This study indicates that pregabalin is a relatively safe drug. Eleven patients (<1.0%) experienced a serious ADR while using the drug. The most frequently reported possible ADRs correspond with the reactions most frequently reported during clinical trials. The study demonstrates that a web-based intensive monitoring system can contribute to greater knowledge about a reaction, such as headache, with quantification and information about latencies and time course of the reaction. It can also detect signals worth further investigation, such as abdominal pain and possible interaction with oral antidiabetics.
- 1 March 2011
- Published by Springer Nature in Drug Safety
- Vol. 34 (3) , 221-231
Intensive Monitoring of Pregabalin
Background: Pregabalin is one of the first drugs registered for the treatment of neuropathic pain. It is also indicated as adjuvant therapy in the treatment of epilepsy and for generalized anxiety disorder. Pregabalin is a GABA analogue and exerts its effect by binding to the α2-δ subunit of voltage-gated calcium channels, leading to a decreased synaptic release of neurotransmitters. Objective: To gain insight into the safety and user profile of pregabalin in daily practice, reported by patients via a web-based intensive monitoring system based at the Netherlands Pharmacovigilance Centre Lareb. Methods: Lareb Intensive Monitoring is an observational prospective cohort study with no limiting inclusion or exclusion criteria compared with clinical trials. First-time users of pregabalin were identified through the first prescription signal in intensive monitoring participating pharmacies between 1 August 2006 and 31 January 2008. Eligible patients received information about the pregabalin study in the pharmacy. When registering online, patient characteristics and information about pregabalin and other concomitant drug use were collected. After registration, the patient received questionnaires by e-mail 2 weeks, 6 weeks, 3 months and 6 months after the start of pregabalin. In these questionnaires, possible adverse drug reactions (ADRs) were addressed. Reactions not labelled in the Summary of Product Characteristics of pregabalin, and reactions that were labelled but were interesting for other reasons, were analysed on a case-by-case basis. Results: In total, 1373 patients filled in the online registration form. The average age of participants was 54.5 years (range 11–89), with 58.0% being female. The indication for pregabalin use was neuropathic pain in 85.9% of participants. The average daily dose was 201 mg, and 80.5% of all users used pregabalin capsule 75 mg. All patients who registered for the study were sent a questionnaire; 1051 (76.5%) patients filled in at least one questionnaire. There were no statistically significant differences found regarding sex, age or daily dosage between this latter group compared with the patients who registered for the study but did not fill in a questionnaire. At least one possible ADR was reported by 69.3% of patients and serious ADRs were reported by 11 patients. The five most frequently reported possible ADRs were dizziness, somnolence, feeling drunk, fatigue and increased weight. Four associations were further analysed. Headache was analysed because of its high frequency. The time to onset ranged from a few hours to 5 months, with a median time to onset of 2 days. In 15 reports the headache passed without withdrawing the drug, and in ten cases the headache disappeared after drug withdrawal. Upper abdominal pain, a possible drug interaction between pregabalin and blood glucose-lowering agents, and suicidal ideation were considered to be signals. Conclusions: Web-based intensive monitoring is an observational prospective cohort study. It will therefore provide a picture of the use of pregabalin and its ADRs in daily practice. This study indicates that pregabalin is a relatively safe drug. Eleven patients (<1.0%) experienced a serious ADR while using the drug. The most frequently reported possible ADRs correspond with the reactions most frequently reported during clinical trials. The study demonstrates that a web-based intensive monitoring system can contribute to greater knowledge about a reaction, such as headache, with quantification and information about latencies and time course of the reaction. It can also detect signals worth further investigation, such as abdominal pain and possible interaction with oral antidiabetics.
- 1 January 2011
- Vol. 155 (42) , A3695
[Adverse drug reactions of a slimming product contaminated with sibutramine].
On the internet numerous diet pills and weight loss courses are advertised. These products may contain active ingredients or contaminants that are not mentioned on the pack or in the patient information leaflet. The Netherlands Pharmacovigilance Centre Lareb received two reports of undesirable effects associated with the unregistered slimming product 'Green Coffee 800'. A 33-year-old woman reported hypomania and a 44-year-old woman reported abnormal hepatic enzyme levels after the use of this product. Research by the Food and Consumer Product Safety Authority revealed that samples of the slimming coffee Green Coffee 800 contained sibutramine. The Dutch Healthcare Inspectorate issued a warning about this product in August 2010. It is plausible that the Green Coffee 800 in the reports sent to Lareb also contained sibutramine. The slimming product Green Coffee 800 may contain sibutramine and may cause severe adverse reactions. This product is still advertised on the Internet.
- 1 January 2011
- Vol. 155 (42) , A3695
[Adverse drug reactions of a slimming product contaminated with sibutramine].
On the internet numerous diet pills and weight loss courses are advertised. These products may contain active ingredients or contaminants that are not mentioned on the pack or in the patient information leaflet. The Netherlands Pharmacovigilance Centre Lareb received two reports of undesirable effects associated with the unregistered slimming product 'Green Coffee 800'. A 33-year-old woman reported hypomania and a 44-year-old woman reported abnormal hepatic enzyme levels after the use of this product. Research by the Food and Consumer Product Safety Authority revealed that samples of the slimming coffee Green Coffee 800 contained sibutramine. The Dutch Healthcare Inspectorate issued a warning about this product in August 2010. It is plausible that the Green Coffee 800 in the reports sent to Lareb also contained sibutramine. The slimming product Green Coffee 800 may contain sibutramine and may cause severe adverse reactions. This product is still advertised on the Internet.
- 1 January 2011
- Published by Springer Nature in Drug Safety
- Vol. 34 (1) , 83-88
Uterine Perforation with the Levonorgestrel-Releasing Intrauterine Device
Background: Levonorgestrel-releasing intrauterine devices (LNG-IUD) are commonly used for contraception and other indications in many countries. National pharmacovigilance centres have been receiving reports from healthcare professionals and patients of uterine perforation associated with the use of these LNG-IUDs. Methods: National pharmacovigilance centres in the Netherlands, New Zealand, Switzerland and Germany did a search on their adverse drug reaction databases for reports of cases of uterine perforation after insertion of a LNG-IUD received between the introduction of the LNG-IUD onto the market in the late 1990s and 15 July 2007. The number of women affected and patient characteristics such as age, parity and breastfeeding status were examined. In addition, the method of detection of the perforation and the time until discovery of the perforation were analysed. Results: Between the introduction of the LNG-IUD onto the market in each country and 15 July 2007, 701 cases of uterine perforation with a LNG-IUD were reported; 8.5% of the perforations were detected at the time of insertion. Abdominal pain and control/check-up visits were the most common events that lead to the detection of a perforation. Of 462 women known to be parous, 192 (42%) were breastfeeding at the time the perforation was discovered. Conclusions: Uterine perforations can be asymptomatic and may remain undetected for a long time after IUD insertion. Abdominal pain, control/ check-up visits or changes in bleeding patterns are triggers for detection of perforation and should therefore be taken seriously.
- 1 January 2011
- Published by Springer Nature in Drug Safety
- Vol. 34 (1) , 83-88
Uterine Perforation with the Levonorgestrel-Releasing Intrauterine Device
Background: Levonorgestrel-releasing intrauterine devices (LNG-IUD) are commonly used for contraception and other indications in many countries. National pharmacovigilance centres have been receiving reports from healthcare professionals and patients of uterine perforation associated with the use of these LNG-IUDs. Methods: National pharmacovigilance centres in the Netherlands, New Zealand, Switzerland and Germany did a search on their adverse drug reaction databases for reports of cases of uterine perforation after insertion of a LNG-IUD received between the introduction of the LNG-IUD onto the market in the late 1990s and 15 July 2007. The number of women affected and patient characteristics such as age, parity and breastfeeding status were examined. In addition, the method of detection of the perforation and the time until discovery of the perforation were analysed. Results: Between the introduction of the LNG-IUD onto the market in each country and 15 July 2007, 701 cases of uterine perforation with a LNG-IUD were reported; 8.5% of the perforations were detected at the time of insertion. Abdominal pain and control/check-up visits were the most common events that lead to the detection of a perforation. Of 462 women known to be parous, 192 (42%) were breastfeeding at the time the perforation was discovered. Conclusions: Uterine perforations can be asymptomatic and may remain undetected for a long time after IUD insertion. Abdominal pain, control/ check-up visits or changes in bleeding patterns are triggers for detection of perforation and should therefore be taken seriously.
- 1 January 2008
- Published by Springer Nature in Drug Safety
- Vol. 31 (6) , 515-524
Adverse Drug Reaction Reporting by Patients in the Netherlands
Background: There has been discussion about the acceptance of adverse drug reactions (ADRs) reported by patients to spontaneous reporting systems. Lack of experience with patient reporting in real life was one of the main drawbacks in this debate. This study covers 3 years of experience with patient reporting in daily practice. We compared patient reports with reports from healthcare professionals. Although patients have the opportunity to report ADRs in several countries, little is published in the literature about the contribution that patient reports have in practice. To our knowledge, this paper is the first to describe long-term experiences with patient reporting as part of a spontaneous reporting system. Methods: The number of reports received, age and sex of the reporters, characteristics of the most frequently reported drugs and characteristics of the ADRs (most frequently reported ADRs, seriousness, outcome) in a 3-year period (April 2004–April 2007) were compared between patient reports and reports from healthcare professionals. Findings: During this 3-year period, the Netherlands Pharmacovigilance Centre Lareb received 2522 reports directly from patients, concerning 5401 ADRs. In the same period, healthcare professionals submitted 10 635 reports, concerning 16 722 ADRs. Differences were found in the categories of seriousness and outcome of the reported ADRs between patients and healthcare professionals. Conversely, similarities between patient reports and reports from healthcare professionals were found in age, sex, most frequently reported ADRs and most frequently reported drugs. Interpretation: Our study highlights clearly that valuable differences between ADR reports from patients and reports from healthcare professionals exist. Differences in interpretation by patients and healthcare professionals may cause the observed disparities in seriousness and outcome of reported ADRs. However, the similarities between patient reports and reports from healthcare professionals in most frequently reported ADRs and most frequently reported drugs are striking. After 3 years of experience with patient reporting, we conclude that patient reporting in spontaneous reporting systems is feasible and that it contributes significantly to a reliable pharmacovigilance.
- 1 January 2008
- Published by Springer Nature in Drug Safety
- Vol. 31 (6) , 515-524
Adverse Drug Reaction Reporting by Patients in the Netherlands
Background: There has been discussion about the acceptance of adverse drug reactions (ADRs) reported by patients to spontaneous reporting systems. Lack of experience with patient reporting in real life was one of the main drawbacks in this debate. This study covers 3 years of experience with patient reporting in daily practice. We compared patient reports with reports from healthcare professionals. Although patients have the opportunity to report ADRs in several countries, little is published in the literature about the contribution that patient reports have in practice. To our knowledge, this paper is the first to describe long-term experiences with patient reporting as part of a spontaneous reporting system. Methods: The number of reports received, age and sex of the reporters, characteristics of the most frequently reported drugs and characteristics of the ADRs (most frequently reported ADRs, seriousness, outcome) in a 3-year period (April 2004–April 2007) were compared between patient reports and reports from healthcare professionals. Findings: During this 3-year period, the Netherlands Pharmacovigilance Centre Lareb received 2522 reports directly from patients, concerning 5401 ADRs. In the same period, healthcare professionals submitted 10 635 reports, concerning 16 722 ADRs. Differences were found in the categories of seriousness and outcome of the reported ADRs between patients and healthcare professionals. Conversely, similarities between patient reports and reports from healthcare professionals were found in age, sex, most frequently reported ADRs and most frequently reported drugs. Interpretation: Our study highlights clearly that valuable differences between ADR reports from patients and reports from healthcare professionals exist. Differences in interpretation by patients and healthcare professionals may cause the observed disparities in seriousness and outcome of reported ADRs. However, the similarities between patient reports and reports from healthcare professionals in most frequently reported ADRs and most frequently reported drugs are striking. After 3 years of experience with patient reporting, we conclude that patient reporting in spontaneous reporting systems is feasible and that it contributes significantly to a reliable pharmacovigilance.
- 6 November 2007
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 17 (1) , 76-81
Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction
Objective Aim of this study is to gain insight in experiences and expectations of general practitioners and specialist doctors regarding the feedback information of the Netherlands Pharmacovigilance Centre Lareb. Method A questionnaire survey was conducted among a random sample of 400 doctors, divided in general practitioners and specialist doctors. Within these groups, a difference was made between those who reported only once and those who are frequent reporters. A structured questionnaire consisted of 23 questions about expectations, experiences, the influence of feedback information and what the doctors would like to change in the feedback from Lareb. A comparison between the groups will give insight in what they think separately and how Lareb can seize on their wishes. Key findings The response rate was 54.4% (n = 217) after one reminder. The respondents are satisfied with the feedback information and regarded the information of good quality. The expectations were higher on information about sources (significance 0.00, caused by specialist doctors who reported once) and co‐medication (0.025 caused by all groups). The experiences of the four groups were also very positive. They all find the feedback information of Lareb reliable, scientifically well considered and to the point. Conclusions General practitioners and specialist doctors are satisfied about the follow‐up information and they like to see the same format of information and communication in the future. Copyright © 2007 John Wiley & Sons, Ltd.
- 6 November 2007
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 17 (1) , 76-81
Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction
Objective Aim of this study is to gain insight in experiences and expectations of general practitioners and specialist doctors regarding the feedback information of the Netherlands Pharmacovigilance Centre Lareb. Method A questionnaire survey was conducted among a random sample of 400 doctors, divided in general practitioners and specialist doctors. Within these groups, a difference was made between those who reported only once and those who are frequent reporters. A structured questionnaire consisted of 23 questions about expectations, experiences, the influence of feedback information and what the doctors would like to change in the feedback from Lareb. A comparison between the groups will give insight in what they think separately and how Lareb can seize on their wishes. Key findings The response rate was 54.4% (n = 217) after one reminder. The respondents are satisfied with the feedback information and regarded the information of good quality. The expectations were higher on information about sources (significance 0.00, caused by specialist doctors who reported once) and co‐medication (0.025 caused by all groups). The experiences of the four groups were also very positive. They all find the feedback information of Lareb reliable, scientifically well considered and to the point. Conclusions General practitioners and specialist doctors are satisfied about the follow‐up information and they like to see the same format of information and communication in the future. Copyright © 2007 John Wiley & Sons, Ltd.
- 5 March 2005
- Vol. 149 (10) , 529-33
[Direct reporting of side effects by the patient: favourable experience in the first year].
To determine the results of establishing a station at which patients can report the side effects of drugs. Descriptive. Since 1 April 2003, patients may submit reports of possible adverse drug reactions directly to the Netherlands Pharmacovigilance Centre Lareb. The reports submitted during the period from 1 April 2003 to 31 March 2004 were analysed and compared with the reports submitted by doctors and pharmacists. In the first year, 276 reports were submitted by patients and 3131 by doctors and pharmacists. The reports from patients usually contained sufficient medical information and more frequently referred to serious adverse reactions than reports by health professionals. The reports from patients relatively often concerned psychotherapeutic agents, notably antidepressants. Based on the positive results during the first year, the Netherlands Pharmacovigilance Centre Lareb has decided to continue the reporting station for patients. Reports submitted by patients are currently part of the core responsibility of Lareb: the detection of signals of new adverse drug reactions.
- 5 March 2005
- Vol. 149 (10) , 529-33
[Direct reporting of side effects by the patient: favourable experience in the first year].
To determine the results of establishing a station at which patients can report the side effects of drugs. Descriptive. Since 1 April 2003, patients may submit reports of possible adverse drug reactions directly to the Netherlands Pharmacovigilance Centre Lareb. The reports submitted during the period from 1 April 2003 to 31 March 2004 were analysed and compared with the reports submitted by doctors and pharmacists. In the first year, 276 reports were submitted by patients and 3131 by doctors and pharmacists. The reports from patients usually contained sufficient medical information and more frequently referred to serious adverse reactions than reports by health professionals. The reports from patients relatively often concerned psychotherapeutic agents, notably antidepressants. Based on the positive results during the first year, the Netherlands Pharmacovigilance Centre Lareb has decided to continue the reporting station for patients. Reports submitted by patients are currently part of the core responsibility of Lareb: the detection of signals of new adverse drug reactions.